NWBO News and Press, Northwest Biotherapeutics Inc. From 12/06/23

Greif Inc. Class A (GEF) is expected to report $1.3 for Q4 2023 Skandinaviska Enskilda Banken - Class A (SVKEF) is expected to report for Q3 2023 Yellow Corporation (YELLQ) is expected to report for Q3 2023 Epiroc AB ADR (EPOKY) is expected to report for Q3 2023 Lakeland Industrie...

Addex Therapeutics Ltd (ADXN) is expected to report $-4 for Q3 2023 Eco Wave Power Global AB (publ) (WAVE) is expected to report for quarter end 2023-09-30 AmeraMex International, Inc. (AMMX) is expected to report for Q3 2023 iClick Interactive Asia Group Limited (ICLK) is expected to...

Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application PR Newswire BETHESDA, Md. , Nov. 22, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax ®...

Tekumo Inc (BCNN) is expected to report for Q3 2023 Diamcor Mining Inc (DMIFF) is expected to report for Q2 2024 American Bio Medica Corp. (ABMC) is expected to report for quarter end 2023-09-30 Northwest Biotherapeutics Inc (NWBO) is expected to report for Q1 2024 Inspired Entert...

The RMR Group Inc. (RMR) is expected to report $0.46 for Q4 2023 Indra Sistemas ADR (ISMAY) is expected to report for Q3 2023 Ceapro Inc. (CRPOF) is expected to report for Q2 2024 Tuya Inc. American Depositary Shares each representing one Class A (TUYA) is expected to report $-0.02 fo...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

Northwest Biotherapeutics Inc (NWBO) is expected to report for Q1 2024

2023-10-14 02:29:27 ET Summary Northwest Bio has provided a timeline for submitting an application for approval to the UK equivalent of the US FDA for their GBM therapy. The company has made significant progress in preparing the Marketing Authorization Application (MAA) for DCVax-...

2023-10-13 10:50:29 ET More on Northwest Biotherapeutics Northwest Bio: Is There Ever Going To Be A Right Time? Financial information for Northwest Biotherapeutics For further details see: NW Bio dips on announcing delay in submission of marketing application for...

Northwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Application PR Newswire BETHESDA, Md. , Oct. 13, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCV...